Skip to main content

UPA and PAI-1 Analysis from Fixed Tissues - New Perspectives for a Known Set of Predictive Markers

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

The urokinase-type plasminogen activator (uPA) and its main inhibitor PAI-1 play key roles in tumorassociated processes such as the degradation of the extracellular matrix (ECM), tissue remodeling, cell adhesion and migration. Elevated expression of both molecules is known to correlate with negative outcomes in node negative breast cancer. To date, these molecules are the only prognostic markers to have reached the highest level of evidence (LOE I) in multi-centered clinical trials for prognosis of node negative breast cancer. Unfortunately, the clinical utility of these molecules as markers is limited by the use of enzyme-linked immunoassay (ELISA) tests for their detection. The ELISA relies on the use of fresh or frozen tissue, which are rarely available in routine clinical settings.

In this review article, we provide an overview of the clinical relevance of uPA and PAI-1 and present alternative methods for their detection. Common uPA and PAI-1 detection methods discussed in literature include RT-PCR-based assays and classical immunohistochemistry approaches. In recent years, attempts have been made to isolate and analyze proteins of formalin fixed, paraffin embedded (FFPE) tissues. These new methods are of special interest because up to now neither RT-PCR nor immunohistochemistry are recommended for the detection of uPA and PAI-1. Here, we present an approach for the analysis of uPA and PAI-1 directly from FFPE tissues that may eventually overcome the limitations of current assays and make the use of both markers widely available for routine prognosis and therapy decisions for breast cancer patients.



Keywords: ASCO; Coomassie staining; DFS; DTT; ELISA; EORTC-RBG; ER; Formalin fixed; Her2; IHC; Immunoblotting; LOE I; NDME; OS; PR; RFS; RNA; RPMA; RPPA; RT-PCR; Reverse Phase Protein Mircoarray; SDS; SDS-PAGE; Urokinase-type plasminogen activator (uPA); VEGF; Western blot; cancer; chemotherapy; extracellular matrix; formalin; highest level of evidence (LOE I); immunohistochemistry; invasion; lymph node; migration; paraffin embedded tissue (FFPE); plasminogen activator inhibitor 1 (PAI-1); protein; proteins

Document Type: Research Article

DOI: https://doi.org/10.2174/092986710793361216

Publication date: 2010-12-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more